Can children swallow tablets? Outcome data from a feasibility study to assess the acceptability of different-sized

Louise Bracken1, Emma McDonough1, Samantha Ashleigh2

  • 1Paediatric Medicines Research Unit, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.

BMJ Open
|October 11, 2020
PubMed

Insights

This study found that 8mm placebo tablets are the most acceptable for children aged 4-12 years. While younger children found larger tablets easier to swallow, taste was rated highly across all age groups.

Area of Science:

  • Pediatric Pharmacology
  • Pharmaceutical Formulation
  • Clinical Feasibility Studies

Background:

  • Tablet acceptability in pediatric populations is crucial for medication adherence.
  • Different tablet sizes and formulations present unique swallowing challenges for children.
  • Limited data exists on the optimal tablet size for pediatric administration.

Purpose of the Study:

  • To assess the feasibility and acceptability of different-sized placebo tablets in children aged 4-12 years.
  • To determine the most acceptable tablet size for pediatric patients.
  • To inform the design of future pediatric medication trials.

Main Methods:

  • A feasibility study conducted in pediatric hospital settings.
  • Participants (children aged 4-12) were given 6mm, 8mm, and 10mm placebo tablets.
  • Swallowing behavior, water consumption, and questionnaire-based acceptability (swallowability, taste) were assessed and stratified by age (4-8 and 9-12 years).

Main Results:

  • The 8mm tablet size was deemed most acceptable by all participants.
  • Younger children (4-8 years) found larger tablets easier to swallow but required more water.
  • Older children (9-12 years) showed minimal preference for tablet size but increased water consumption with larger tablets.

Conclusions:

  • Tablets represent a potentially acceptable formulation for pediatric patients aged 4-12 years.
  • The 8mm tablet size is recommended for this age group based on acceptability.
  • Recruitment strategies for pediatric medication acceptability studies require careful consideration, with recruitment of staff children proving effective.
Abstract

Related Concept Videos

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
100
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
70
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
90
The Placebo Effect01:54

The Placebo Effect

The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
6.6K
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
101
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
134